Literature DB >> 29860604

Preclinical study of the antitumor effect of sphingosine-1-phosphate receptor 1 antibody (S1PR1-antibody) against human breast cancer cells.

Shujun Xiao1, Jian Yang2.   

Abstract

Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite, which regulates a broad range of physiological and pathophysiological processes. The signaling of S1P via its cell surface receptor S1PR1 has been identified to play an important role in carcinogenesis, cancer growth and survival, and tumor metastasis. In this study, we evaluated whether a monoclonal antibody against S1PR1 (S1PR1-antibody) could impose any effect on cell growth of human breast cancer SK-BR-3 and MDA-MB-231 cells. The S1PR1-antibody exhibited cytostatic effect against both cell lines at the concentration of 4000 ng/mL. Co-administration of 4000 ng/mL of the S1PR1-antibody not only potentiated the cytotoxicity of carboplatin towards the MDA-MB-231 cells but also increased the anti-proliferative effect of S1P towards the SK-BR-3 cells. Furthermore, we showed that co-administration of S1P did not sensitize the SK-BR-3 and MDA-MB-231 cells towards carboplatin.

Entities:  

Keywords:  Carboplatin; HER2 subtype breast cancer; S1PR1-antibody; Sphingosine-1-phosphate; Triple-negative subtype breast cancer

Mesh：

Substances：

Year:  2018        PMID： 29860604     DOI： 10.1007/s10637-018-0618-5

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  35 in total

Review 1.  Sphingolipid metabolism in cancer signalling and therapy.

Authors:  Besim Ogretmen
Journal:  Nat Rev Cancer       Date:  2017-11-17       Impact factor: 60.716

Review 2.  Sphingosine 1-phosphate and cancer.

Authors:  Nigel J Pyne; Ashref El Buri; David R Adams; Susan Pyne
Journal:  Adv Biol Regul       Date:  2017-09-15

3.  Targeting sphingosine kinase-1 to inhibit melanoma.

Authors:  SubbaRao V Madhunapantula; Jeremy Hengst; Raghavendra Gowda; Todd E Fox; Jong K Yun; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2012-03       Impact factor: 4.693

Review 4.  The alliance of sphingosine-1-phosphate and its receptors in immunity.

Authors:  Juan Rivera; Richard L Proia; Ana Olivera
Journal:  Nat Rev Immunol       Date:  2008-10       Impact factor: 53.106

5.  Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer.

Authors:  Eriko Katsuta; Li Yan; Masayuki Nagahashi; Ali Raza; Jamie L Sturgill; Debra E Lyon; Omar M Rashid; Nitai C Hait; Kazuaki Takabe
Journal:  J Surg Res       Date:  2017-06-29       Impact factor: 2.192

6.  Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis.

Authors:  Nobuaki Igarashi; Taro Okada; Shun Hayashi; Toshitada Fujita; Saleem Jahangeer; Shun-ichi Nakamura
Journal:  J Biol Chem       Date:  2003-09-02       Impact factor: 5.157

Review 7.  "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets.

Authors:  Kazuaki Takabe; Steven W Paugh; Sheldon Milstien; Sarah Spiegel
Journal:  Pharmacol Rev       Date:  2008-06-13       Impact factor: 25.468

8.  Sphingosine kinase 2 prevents the nuclear translocation of sphingosine 1-phosphate receptor-2 and tyrosine 416 phosphorylated c-Src and increases estrogen receptor negative MDA-MB-231 breast cancer cell growth: The role of sphingosine 1-phosphate receptor-4.

Authors:  Jan Ohotski; Hugh Rosen; Robert Bittman; Susan Pyne; Nigel J Pyne
Journal:  Cell Signal       Date:  2014-01-29       Impact factor: 4.315

Review 9.  Platinum resistance in breast and ovarian cancer cell lines.

Authors:  Niels Eckstein
Journal:  J Exp Clin Cancer Res       Date:  2011-10-04

Review 10.  Sphingosine kinase 1 as an anticancer therapeutic target.

Authors:  Ying Gao; Fei Gao; Kan Chen; Mei-li Tian; Dong-li Zhao
Journal:  Drug Des Devel Ther       Date:  2015-06-23       Impact factor: 4.162
View more
  6 in total

Review 1.  S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy.

Authors:  Narges Rostami; Afshin Nikkhoo; Amir Ajjoolabady; Gholamreza Azizi; Mohammad Hojjat-Farsangi; Ghasem Ghalamfarsa; Bahman Yousefi; Mehdi Yousefi; Farhad Jadidi-Niaragh
Journal:  Mol Diagn Ther       Date:  2019-08       Impact factor: 4.074

2.  S1PR1 regulates the switch of two angiogenic modes by VE-cadherin phosphorylation in breast cancer.

Authors:  Shuang Liu; Chunsheng Ni; Danfang Zhang; Huizhi Sun; Xueyi Dong; Na Che; Xiaohui Liang; Chen Chen; Fang Liu; Jingru Bai; Xian Lin; Xiulan Zhao; Baocun Sun
Journal:  Cell Death Dis       Date:  2019-02-27       Impact factor: 8.469

Review 3.  Roles of sphingosine-1-phosphate signaling in cancer.

Authors:  Peng Wang; Yonghui Yuan; Wenda Lin; Hongshan Zhong; Ke Xu; Xun Qi
Journal:  Cancer Cell Int       Date:  2019-11-14       Impact factor: 5.722

4.  Key drug-targeting genes in pancreatic ductal adenocarcinoma.

Authors:  Meena Kishore Sakharkar; Sarinder Kaur Dhillon; Mohit Mazumder; Jian Yang
Journal:  Genes Cancer       Date:  2021-03-11

Review 5.  Microfluidization trends in the development of nanodelivery systems and applications in chronic disease treatments.

Authors:  Palanivel Ganesan; Govindarajan Karthivashan; Shin Young Park; Joonsoo Kim; Dong-Kug Choi
Journal:  Int J Nanomedicine       Date:  2018-10-09

6.  Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers.

Authors:  Limei Zhong; Linling Xie; Zhiyong Yang; Lijuan Li; Shaohua Song; Donglin Cao; Yufeng Liu
Journal:  BMC Cancer       Date:  2020-08-15       Impact factor: 4.430
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.